TD Cowen analyst Tyler Van Buren initiated coverage of Artiva Biotherapeutics with a Buy rating and no price target. The firm says many cell therapy players are entering the autoimmune space but that Artiva’s approach is unique. The company’s AlloNK has demonstrated “impressive efficacy” and safety in non-Hodgkin lymphoma, which should translate to success in autoimmune indications, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTV:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue